- Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have submitted an FDA Emergency Use Authorization (EUA) application for a 10-µg booster dose of COVID-19 Vaccine for children 5 through 11 years of age.
- The submission included data from the Phase 2/3 clinical trial in children ages 5 through 11 years who received a booster dose approximately six months after the second dose of the Pfizer-BioNTech COVID-19 Vaccine 10-µg two-dose primary series.
- Related: Pfizer/BioNTech's COVID-19 Vaccine Booster Shows High Immune Response In Kids Aged 5-11 Years.
- The companies also plan to submit these data to the European Medicines Agency and other regulatory agencies for authorization in the coming weeks.
- Also Read: FDA Postpones Adcomm For Pfizer's COVID-19 Vaccine For Youngest Kids.
- Price Action: PFE shares are up 0.53% at $49.29, and BNTX stock is up 0.72% at $149.01 during the premarket session on the last check Wednesday.
- Photo by x3 from Pixabay
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Pfizer, BioNTech Seeks Emergency Use Nod For COVID-19 Vaccine For Kids 5-11 Years
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks